Compare GORO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | NERV |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.0M | 228.5M |
| IPO Year | 2010 | 2014 |
| Metric | GORO | NERV |
|---|---|---|
| Price | $1.49 | $5.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | $1.63 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.7M | 322.6K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.80 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,759,000.00 | $41,175,600.00 |
| Revenue This Year | $25.99 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 51.78 | N/A |
| 52 Week Low | $0.35 | $1.30 |
| 52 Week High | $1.87 | $12.46 |
| Indicator | GORO | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 42.41 |
| Support Level | $1.27 | $5.02 |
| Resistance Level | $1.75 | $6.69 |
| Average True Range (ATR) | 0.10 | 0.59 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 79.57 | 17.83 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.